Greenwood Capital Associates LLC Has $292,000 Position in TherapeuticsMD Inc (TXMD)
Greenwood Capital Associates LLC increased its stake in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 173.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 55,486 shares of the company’s stock after buying an additional 35,177 shares during the period. Greenwood Capital Associates LLC’s holdings in TherapeuticsMD were worth $292,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Managed Account Services Inc. boosted its position in shares of TherapeuticsMD by 5.5% in the second quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock valued at $101,000 after buying an additional 1,000 shares during the period. Traynor Capital Management Inc. boosted its position in shares of TherapeuticsMD by 14.0% in the second quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock valued at $123,000 after buying an additional 2,799 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after buying an additional 10,330 shares during the period. Carl Domino Inc bought a new position in shares of TherapeuticsMD during the second quarter valued at about $235,000. Finally, Oppenheimer & Co. Inc. boosted its position in shares of TherapeuticsMD by 94.5% in the first quarter. Oppenheimer & Co. Inc. now owns 41,466 shares of the company’s stock valued at $298,000 after buying an additional 20,148 shares during the period.
TherapeuticsMD Inc (NASDAQ TXMD) opened at 6.03 on Thursday. The company has a 50-day moving average price of $5.58 and a 200-day moving average price of $5.54. The firm’s market cap is $1.23 billion. TherapeuticsMD Inc has a 12-month low of $3.50 and a 12-month high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The business had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $4.91 million. TherapeuticsMD had a negative net margin of 462.94% and a negative return on equity of 77.41%. The business’s revenue was down 3.4% on a year-over-year basis. During the same period last year, the firm posted ($0.11) earnings per share. On average, equities analysts predict that TherapeuticsMD Inc will post ($0.42) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/greenwood-capital-associates-llc-has-292000-position-in-therapeuticsmd-inc-txmd/1534036.html.
Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $33.00 price objective on shares of TherapeuticsMD in a report on Tuesday, August 15th. CIBC reissued a “market perform” rating and issued a $12.00 price objective on shares of TherapeuticsMD in a report on Tuesday, May 9th. Zacks Investment Research cut TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Deutsche Bank AG initiated coverage on TherapeuticsMD in a report on Friday, July 21st. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 price target on shares of TherapeuticsMD in a report on Monday, August 21st. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $16.14.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.